The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital (Department of Surgery), Zhengzhou, China.
The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital (Department of Immunotherapy), Zhengzhou, China.
Int Immunopharmacol. 2024 May 10;132:111988. doi: 10.1016/j.intimp.2024.111988. Epub 2024 Apr 8.
Clinical application of immunotherapy represented by Programmed Death-1 (PD-1) monoclonal antibody has changed the treatment paradigm for colorectal cancer (CRC), and tumor-infiltrating T lymphocytes are critical for anti-PD-1 therapy in CRC. However, there are few studies on the relationship between the expression CXCR3 on T lymphocytes and the clinical aspects of CRC. In this study, we analyzed the expression levels of CXCR3 and PD-1 in CD8 and CD4 T lymphocytes in healthy donors (HDs) and patients with CRC.
We detected the expressions of CXCR3 and PD-1 on T lymphocytes in peripheral blood of healthy donors as well as peripheral blood, tumor tissue and para-cancerous tissues of patients with CRC using flow cytometry. We also analyzed the relationship between the expressions of CXCR3 and PD-1 on T lymphocytes and the pathological characteristics of CRC using t test.
Expression of CXCR3 on tumor-infiltrating T lymphocytes was lower, whereas the expression of PD-1 was higher than that on para-cancerous tissues and PB in patients with CRC. In patients with lymph node metastasis of CRC, the expressions levels of CXCR3 PD-1 on tumor-infiltrating CD8 and CD4 T lymphocytes were higher than those in patients without lymph node metastasis. The levels of CXCR3 PD-1 expressions differed depending on the primary tumor site.
Expressions of CXCR3 and PD-1 on tumor-infiltrating T lymphocytes are related to the development of CRC and metastasis, providing clues for exploring the pathogenesis of CRC and developing new strategies for tumor immunotherapy.
以程序性死亡受体-1（PD-1）单克隆抗体为代表的免疫疗法的临床应用改变了结直肠癌（CRC）的治疗模式，肿瘤浸润 T 淋巴细胞是 CRC 抗 PD-1 治疗的关键。然而，关于 T 淋巴细胞上 CXCR3 的表达与 CRC 的临床方面之间的关系的研究较少。在这项研究中，我们分析了健康供体（HD）和 CRC 患者的 CD8 和 CD4 T 淋巴细胞上 CXCR3 和 PD-1 的表达水平。
我们使用流式细胞术检测了健康供体外周血以及 CRC 患者外周血、肿瘤组织和癌旁组织中 T 淋巴细胞上 CXCR3 和 PD-1 的表达。我们还使用 t 检验分析了 T 淋巴细胞上 CXCR3 和 PD-1 的表达与 CRC 的病理特征之间的关系。
CRC 肿瘤浸润 T 淋巴细胞上 CXCR3 的表达较低，而 PD-1 的表达则高于癌旁组织和 PB。在 CRC 有淋巴结转移的患者中，肿瘤浸润性 CD8 和 CD4 T 淋巴细胞上 CXCR3 PD-1 的表达水平高于无淋巴结转移的患者。CXCR3 PD-1 的表达水平取决于原发肿瘤部位。
肿瘤浸润 T 淋巴细胞上 CXCR3 和 PD-1 的表达与 CRC 的发展和转移有关，为探索 CRC 的发病机制和开发新的肿瘤免疫治疗策略提供了线索。
